Guillain-Barré syndrome after treatment with sunitinib malate?
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor used for treatment of renal cell carcinoma and gastrointestinal stromal tumor. We report a case of a patient who developed Guillain-Barrd syndrome after initial treatment with sunitinib, with recurrent symptoms upon reintroducing the drug. This is the first report of such an effect. The literature on chemotherapy-induced Guillain-Barri syndrome is also reviewed. Oncology providers should be aware of this rare but potentially serious possible adverse effect of sunitinib.
Mulherin
Brian
B
Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison, USA.
Loconte
Noelle K
NK
Holen
Kyle D
KD
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D020275:Guillain-Barre Syndrome / Q000139:chemically induced*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib